135 related articles for article (PubMed ID: 18534872)
21. Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma.
Zeng C; Ke ZF; Yang Z; Wang Z; Yang SC; Luo CQ; Wang LT
Med Oncol; 2012 Sep; 29(3):2234-9. PubMed ID: 22009216
[TBL] [Abstract][Full Text] [Related]
22. Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions.
Chen W; Lee Z; Awadallah A; Zhou L; Xin W
Diagn Pathol; 2020 Jul; 15(1):92. PubMed ID: 32703222
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
Wright GL; Grob BM; Haley C; Grossman K; Newhall K; Petrylak D; Troyer J; Konchuba A; Schellhammer PF; Moriarty R
Urology; 1996 Aug; 48(2):326-34. PubMed ID: 8753752
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Sweat SD; Pacelli A; Murphy GP; Bostwick DG
Urology; 1998 Oct; 52(4):637-40. PubMed ID: 9763084
[TBL] [Abstract][Full Text] [Related]
26. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
[TBL] [Abstract][Full Text] [Related]
27. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
Vallabhajosula S; Nikolopoulou A; Babich JW; Osborne JR; Tagawa ST; Lipai I; Solnes L; Maresca KP; Armor T; Joyal JL; Crummet R; Stubbs JB; Goldsmith SJ
J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.
Mannweiler S; Amersdorfer P; Trajanoski S; Terrett JA; King D; Mehes G
Pathol Oncol Res; 2009 Jun; 15(2):167-72. PubMed ID: 18802790
[TBL] [Abstract][Full Text] [Related]
29. PSMA expression is highly homogenous in primary prostate cancer.
Tsourlakis MC; Klein F; Kluth M; Quaas A; Graefen M; Haese A; Simon R; Sauter G; Schlomm T; Minner S
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):449-55. PubMed ID: 26153794
[TBL] [Abstract][Full Text] [Related]
30. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
Milowsky MI; Nanus DM; Kostakoglu L; Sheehan CE; Vallabhajosula S; Goldsmith SJ; Ross JS; Bander NH
J Clin Oncol; 2007 Feb; 25(5):540-7. PubMed ID: 17290063
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
32. [Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma].
Ren JQ; Chen ZQ; Zheng L; Chen Q; Li H; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):735-8. PubMed ID: 15733392
[TBL] [Abstract][Full Text] [Related]
33. PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.
Bychkov A; Vutrapongwatana U; Tepmongkol S; Keelawat S
Sci Rep; 2017 Jul; 7(1):5202. PubMed ID: 28701709
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
Kranzbühler B; Salemi S; Umbricht CA; Müller C; Burger IA; Sulser T; Eberli D
Prostate; 2018 Jul; 78(10):758-765. PubMed ID: 29633296
[TBL] [Abstract][Full Text] [Related]
35. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
[TBL] [Abstract][Full Text] [Related]
37. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
38. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
39. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
Minner S; Wittmer C; Graefen M; Salomon G; Steuber T; Haese A; Huland H; Bokemeyer C; Yekebas E; Dierlamm J; Balabanov S; Kilic E; Wilczak W; Simon R; Sauter G; Schlomm T
Prostate; 2011 Feb; 71(3):281-8. PubMed ID: 20809553
[TBL] [Abstract][Full Text] [Related]
40. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
Murphy GP; Elgamal AA; Su SL; Bostwick DG; Holmes EH
Cancer; 1998 Dec; 83(11):2259-69. PubMed ID: 9840525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
